Zhao Ming was appointed as the associate chief physician, associate professor and advisor of master’s degree student at Sun Yat-sen University Cancer Center. He is familiar with human imaging anatomy and imaging vascular anatomy and proficient in interventional diagnosis and treatment for solid tumors, such as interventional chemoembolization and radiofrequency ablation of primary liver cancer and metastatic colorectal cancer, integrated application of molecular targeted therapy, radiofrequency ablation of lung cancer and lung metastatic tumors and integrated application of TACE, TAI and molecular targeted therapy; palliative treatment for advanced tumors, such as drainage of and stent implantation of obstructive jaundice, stent implantation in the esophagus, stent implantation in the vena cava, image-guided implantation of radioactive particles under, nerve compression and interventional treatment for pain palliation of metastatic bone tumors. He is able to grasp the developments in cancer treatment and provide out-patient medical advice and popularization of science, and attends clinical and multidisciplinary consultations on hepatobiliary diseases for chief scientists. With regard to single diseases, he owns an in-depth research on and abundant clinical experience in hepatic metastases, which he also regards as his basis for research.

Guided by the concept of single disease sand multidisciplinary integrated treatment, he systematically carries out clinical research on liver tumors and solid tumors in the lung and gradually implements the concept of integrating interventional treatment and minimally invasive surgery planning system into individualized treatment; conducts real-time ablation treatment for tumors under the guidance of MRI and performs local treatment for such solid cancers as liver cancer, lung cancer and retroperitoneal cancer with various means of minimally invasive surgery including nano-knife. Taking prolong survival as the goal, he analyzes factors concerning the systemic immunity of tumors’ recurrence and gradually takes measures of intervention clinical treatment by studying immune regulation of recurrent primary liver cancer and its immune tolerance mechanism.

January 2014: appointed as the Chief Physician of Sun Yat-sen University Cancer Center;
April 2011-September 2013: studied at Brigham and Women’s Hospital, Harvard University and worked on medical research on basis for immunology and transformation of tumors;

September 2008: short-term study in Barcelona Clinic Liver Cancer (BCLC);
2002-2006: Studied interventional treatment and minimally invasive surgery for liver cancer and obtained the doctoral degree in oncology;

1997-2000: received specialist training of cancer and obtained a master’s degree in oncology from Sun Yat-sen University (former Sun Yat-sen University of Medical Sciences);

1993-1997: completed clinical training for resident physicians at the First Affiliated Hospital of Bengbu Medical College

 

1. Percutaneous CT-guided radiofrequency ablation as supplemental therapy after systemic chemotherapy for selected advanced non-small cell lung cancers. Am J Roentgenol.2013;201(6):1362-7.

2. Transcriptomic profiling of Aspergillusflavus in response to 5-azacytidine. Fungal Genet Biol. 2013;56:78-86.

3. Chromosomal evolution of Escherichia coli for the efficient production of lycopene. BMC Biotechnol 2013;13(1):6.

4. Percutaneous CT-guided radiofrequency ablation for unresectable hepatocellular carcinoma pulmonary metastases. International Journal of Hyperthermia 2012;28:721-728.

5. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012;81(10):2717-2725.

6. Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation. Eur J Radiol 2012;81(4):e473-e477.

7. Retroperitoneal schwannoma treated with percutaneous computed tomography-guided radiofrequency ablation. J Neurosurg Spine 2012;17(2):173-176.

8. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature. Exp Ther Med 2012; 4:334-338

9. CT-guided radiofrequency ablation prolonged metastatic survival in patients with liver metastases from nasopharyngeal carcinoma. Int J Hyperthermia 2011; 27(6):549-554.

10. Huge refractory retroperitoneal nerve sheath tumor treated with radiofrequency ablation: a case report with literature review. Chin J Cancer 2010; 29(4):463-6.

Updated by International Office, Sun Yat-sen University Cancer Center